INTRODUCTION
Follistatin is a structurally complex molecule that is comprised of 344 residues. It is generally accepted that two major isoforms of follistatin are present in humans which are a result of alternative mRNA splicing: follistatin-315 (FST315) and follistatin-288 (FST288) (reviewed in (Phillips and De Kretser 1998) . Both protein isoforms contain identical core regions that are formed from a series of tandemly repeated domain elements: A N-terminal domain (FST 0), followed by three successive KAZAL/EGF-like repeats units (deemed FST 1, 2 and 3) and in the case of FST315, a highly acidic C-terminal tail is presented (Keutmann, Schneyer et al. 2004) ( Figure 1 ). The primary sequence of follistatin is punctuated by a preponderance of cysteine residues which form 18 disulfide bonds that interlink the aforementioned domain elements and that stabilize the overall protein structure. The molecular complexity of follistatin is further exacerbated by the presence of three putative N-linked glycosylation sites at asparagines residues in positions 95, 112 and 259 ( Figure 1 ). These structural elements provide a scaffold which allows follistatin to interact with and regulate the activities of several members of the TGFβ-like family of proteins, including activins (reviewed in (Phillips and De Kretser 1998)), growth differentiation factors (GDFs) (Amithor, Nicholas et al. 2004; Sidis, Keutmann et al. 2006; Schneyer, Sidis et al. 2008 ) and bone morphogenic proteins (BMPs) (Iemura, Yamamoto et al. ;
J P E T # 2 0 1 4 9 1 7 muscle injury could be obtained only when local intramuscular (IM) delivery was performed, but not with subcutaneous delivery. Our data suggested the lack of effect after subcutaneous administration of FST315 was likely due to the rapid clearance kinetics exhibited by the molecule. Therefore, to improve upon the suboptimal pharmacokinetic properties of follistatin, we engineered a novel FST315 chimeric fusion protein fused with murine IgG1 Fc region (FSTFc). These alterations were sufficient to dramatically alter the pharmacokinetic profile of FSTFc in healthy mice and induce systemic effects with subcutaneous delivery in a mouse model of muscle injury. We were able to further improve upon the pharmacokinetic profile of FST-Fc by removing the native heparan sulfate binding activity of follistatin (FST-ΔHBS-Fc), which lead to robust, dose-dependent, systemic effects that could be achieved with weekly subcutaneous dosing regimens. Taken together, our findings highlight the exquisite interplay between balancing and optimizing multiple factors on the overall PK/PD properties of follistatin to provide the first example of a systemically-viable follistatin-based biotherapeutic.
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MATERIALS AND METHODS

Construction, expression and purification of recombinant follistatin variant proteins
The follistatin variants described within this report were expressed in stably-transfected
Chinese hamster ovary cells and were generated at Eli Lilly (Indianapolis, IN, USA). Isolation of native FST315 containing a C-terminal hexahistidine tag from concentrated cell culture supernatants proceeded via a two step purification method. In a first step, crude conditioned cell culture media containing FST315 was captured using Nickel-charged chelating sepharose (GE Healthcare, Waukesha, WI), Bound FST315 protein was eluted using a step gradient of Imidazole and pooled fractions were concentrated using a Amicon Ultra-15 concentrator (Millipore, Billerica, MA) and further purified using a Superdex G200 preparative gel filtration step (GE Healthcare, Waukesha, WI). Finally protein purity was assessed using both simplyblue stained (Life Technologies, Carlsbad, CA) SDS-PAGE gel analysis and analytical gel filtration on a TSKG3000SWXL column (Tosho Bioscience, Toyko, Japan) and was generally found to be >95%.
Isolation of FST-Fc and FST-ΔHBS-Fc chimeric proteins from concentrated cell culture supernatants was performed using a two step purification method. In the first step, crude conditioned cell culture media containing either FST-Fc or FST-ΔHBS-Fc was captured onto monoclonal antibody (mAb) select sepharose (GE Healthcare, Waukesha, WI) affinity chromatography under high salt conditions (1M sodium chloride) and eluted using a stepgradient of 10 mM sodium citrate, pH 3.0. Pooled protein was concentrated using an Amicon Ultra-15 concentrator (Millipore, Billerica, MA) and further purified using a Superdex G200 preparative gel filtration step (GE Healthcare, Waukesha, WI). These steps generally resulted in
protein purity of >95%, as assessed by simply-blue stained (Life Technologies, Carlsbad, CA) SDS-PAGE and analytical gel filtration on a TSKG3000SWXL column (Tosho Bioscience, Tokyo, Japan).
Heparin Sepharose Binding Chromatographic Assay
The interaction of the follistatin variants with heparin was measured using a chromatographic method in which approximately 100 μg of each follistatin variant in Hyclone Phosphate Buffer Saline (1X) (Thermo Fisher Scientific, Waltham, MA) was injected using an Agilent 1100 HPLC onto a 1 mL heparin sepharose fastflow column (GE Healthcare, Waukesha, WI) which had been equilibrated in 20 mM potassium phosphate, pH 7.0. Bound protein was eluted using a linear gradient of 0-100% 20 mM potassium phosphate, 1 M sodium chloride, pH 7.0 and extent of heparan sulfate binding activity was assessed based on observed column retention (measured in minutes) and the required concentration of sodium chloride to elute the bound protein from the column.
SMAD Binding Element 12 (SBE12) Luciferase-based Reporter Gene Assay
HEK293 cells stably expressing the SBE-12-luciferase system (Qiagen, Venlo, Netherlands)
were seeded 50,000 to 100,000 cells/well/100 μl DMEM/F12 (Life Technologies, Carlsbad, CA) In all the studies, the mouse blood samples were collected by saphenous vein, tail clip, retro-orbital or cardiac puncture into tubes containing sodium EDTA as anticoagulant and processed to plasma for subsequent analyses.
Bioanalytical assays for the pharmacokinetic samples and pharmacokinetic data analysis
This article has not been copyedited and formatted. The final version may differ from this version. Plasma concentration-time data were calculated using a model-independent approach based on the statistical moment theory. The parameters calculated included the maximum plasma concentration (C max ), area under the curve (AUC 0-∞ ), clearance (CL), and elimination half-life (t 1/2 ).
Murine pharmacodynamic studies
All mouse experiments were performed with the approval of Institutional Animal Care and Use Committee and are in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Muscle injury was conducted using a 100 μL injection of a 10 μM cardiotoxin ( and immobilization, CTX injections were performed as described above and were subjected to hindlimb immobilization with the employment of Vet-Lite casting (Jorgensen Labs, Loveland, CO). Intravenous or subcutaneous dosing of the follistatin variants commenced three hours following the intramuscular injection of cardiotoxin and the injured gastrocnemius muscles were subsequently harvested at specified timepoints to assess muscle mass.
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RESULTS
In vitro binding properties, pharmacokinetics and pharmacodynamics of follistatin in mice
FST is post-translationally spliced into two distinct isoforms, FST288 and FST315, which differ by the presence of a highly acidic domain in the 315 isoform. In early comparisons of these two isoforms, we found FST288 to exhibit poor protein expression and purification attributes, relative to FST315 (data not shown). As a result of these initial studies, FST315 was found to be a more suitable platform for engineering and the studies described herein focused solely on this variant. As described in the methods section, we utilized a C-terminal hexahistidine tag on FST315 for ease of purification. The histidine tagged FST315 binds directly to and inhibits both activin A and GDF8/myostatin from binding to their mutually shared cognate receptor (Activin A Type II receptor) in a SMAD 2/3 reporter gene cell-based assay (Table 1 ). The potency of the histidine tagged FST315 was similar to commercially available follistatin (R&D Systems) when compared in our SMAD 2/3 reporter assay (data not shown), indicating the tag did not have an influence on the activity of FST315 in vitro. Given these data, we used the histidine tagged FST315 for all the pharmacokinetic and pharmacodynamic studies described herein.
After a single IV or SC administration of 3 mg/kg to mice, FST315 was cleared rapidly from the circulation (Figure 2A ). FST315 was characterized by a mean clearance and half-life of 5269 mL/h/kg and two hours in mice, respectively, after the IV dose ( Table 2 ). The SC bioavailability (%F) was ~ 90% (Table 2) inhibition of myostatin helps expedite muscle repair (reviewed in (Sharma, Langley et al. 2001) ).
Evaluation of the pharmacodynamics of FST315 in mice showed the protein did not significantly increase muscle mass (as assessed in the gastrocnemius) or body weight following daily SC administrations of 1 or 5 mg/kg for seven days (Figure 3 ). However, FST315 displayed an improvement in muscle mass (~14%) when administered IM at 0.5 mg/kg daily to the atrophied muscle in mice for seven days (Figure 3 ). These data suggested the lack of effect after the SC administration to mice was likely due to poor exposure and/or distribution to the muscle tissue.
Fusion of FST315 to a murine IgG 1 Fc
Given native FST315 showed a modest effect on muscle in mice after a local (IM) administration, we were prompted to fuse follistatin to a murine IgG 1 Fc determine the in vitro Table 1A shows the consequence of these combined modifications on the inhibitory activity of FST-Fc towards Activin A and GDF8 in our SMAD 2/3 reporter cell-based assay. Relative to unmodified FST315, FST-Fc resulted in a 6.3-fold and 18-fold improvement towards Activin A and GDF8, respectively. These results indicate that addition of the Fc, and subsequent dimerization of native FST315, leads to significant improvement of ligand binding activity of follistatin in vitro.
The average pharmacokinetic concentration-time profiles for the FST-Fc are shown in Figure   2B . FST-Fc was characterized with ~200-fold and ~30-fold improved the exposure (AUC) and half-life, respectively, in mice relative to FST315 after IV administration ( Figure 2B and Table   2 ). After a single IV administration of 3 mg/kg to mice, FST-Fc was characterized by a mean clearance and half-life of ~ 28 mL/h/kg and ~ 60 hours in mice, respectively ( Table 2) bioavailability (%F) of FST-Fc was ~ 60%. In this evaluation we also extended the duration of the dose (14 days versus seven for the FST315 studies) to provide ample opportunity for the molecules to produce a systemic effect in mass and to overcome the potential limitations of the FST-Fc molecule in regards to its ability to interact with heparan sulfate (discussed further below). Evaluation of the pharmacodynamics of FST-Fc in our cardiotoxin induced mouse muscle atrophy model also showed FST-Fc increased gastrocnemius muscle mass (~6%) after daily SC administration for 14 days (Figure 4) .
Effect of the removal of the heparan sulfate binding site on the in vitro ligand binding, pharmacokinetic and pharmacodynamic properties of FST-Fc
We chose to remove the heparan sulfate binding region in our FST-Fc construct using the mutation described by Sidis et al (Sidis, Schneyer et al. 2005) and assess the influence of this removal on the in vitro ligand binding and PK/PD properties of the molecule. Heparan sulfate binding was assessed using a heparin sepharose chromatographic approach which assessed binding of each follistatin variant as a function of sodium chloride concentration required to remove bound molecules. Unmodified FST315 showed a strong affinity towards heparin as evidenced by the high concentrations of salt (< 500 mM) required for eluting the compound from the heparin affinity column. The Fc did not readily alter these heparin binding characteristics (Table 1B) . However, we did observe a clear decrease FST-ΔHBS-Fc heparin binding activity as evidenced by a substantial reduction in the amount of salt (120 mM) required to elute bound protein from the heparin affinity column (Table 1B) . These data coupled with those found in The average pharmacokinetic concentration verusus time profiles for FST-Fc and FST-ΔHBS-Fc are shown in Figure 2B and 2C, respectively. The FST-ΔHBS-Fc molecule showed ~4.8-fold slower clearance (CL) and ~2-fold longer elimination phase half-life relative to the FST-Fc in mice ( Figure 2C and Table 2 ). We further evaluated the pharmacodyamic effects of FST-ΔHBS- There is a paucity of studies around the PK and PD of systemically administered follistatin.
To date, only a single investigation into these relationships has been performed in the context of a mouse model of liver regeneration following 70% hepatectomy (Kogure, Omata et al. 1995; Kogure, Zhang et al. 1996) . In this study, a relatively low dose (1 μg) of recombinant native FST288 was administered via intraportal infusion to rats following a partial (70%) hepatectomy.
The authors showed that this relatively low dose of drug was capable of inducing increasing liver regeneration rates and remnant liver weight, relative to control treated animals (Kogure, Omata . 1995) . However, no effect on liver was observed following a single intravenous infusion the protein (Kogure, Omata et al. 1995) . In a follow-up study, a pharmacokinetic evaluation of FST288 following IV administration showed a pronounced rapid clearance and short (t 1/2 ~ 130 min) of 125 I-labeled compound. Thus, these studies suggest the lack of pharmacology after IV administration was likely due to the limited tissue distribution and/or rapid systemic clearance of follistatin. Consistent with these reports, our data investigating the PK/PD relationship of the more acidic variant, FST315, in the context of normal mice and in a mouse model of muscle injury show that repeated SC administration is unable to induce a significant increase in the mass in the injured muscle ( Figure 3) . Conversely, when FST315 was administered IM, at a fraction of the highest subcutaneous dose tested, a robust increase in muscle mass that approaches the uninjured muscle mass was observed (Figure 3 ). This dependence on delivery route was clarified by pharmacokinetic assessment of FST315 in mice in which both IV and SC administration resulted in rapid systemic clearance and short circulating half-life ( Figure 2A and Table 2 ). Taken together, our data suggests FST315 is active in increasing muscle mass when it reaches the target tissue, however its poor pharmacokinetic properties do not allow sufficient concentrations of drug to accumulate at muscle following systemic administration to induce the intended pharmacology.
Our initial PK/PD findings with systemically administered FST315 are not entirely surprising given the previous reports (Kogure, Zhang et al. 1996) , as well as, the biochemical properties of the protein. It is quite possible that some of our systemically administered FST315 may have been cleared through renal filtration since the molecular weight of FST315 is ~38 kDa.
Previous, studies with 125 I-labeled follistatin support this hypothesis (Kogure, Zhang et al. 1996) .
In addition to the molecular weight of follistatin enhancing the clearance of the protein, the This article has not been copyedited and formatted. The final version may differ from this version. within proteins are known to facilitate rapid systemic clearance mediated by binding to cell surface heparan sulfate present on vascular endothelial cells (reviewed in (Bernfield, Gotte et al. 1999) ). Our studies with FST315 indicate strong heparin binding activity, as evidenced by high ionic strength required for elution from the heparin column (Table 1B) . These properties of follistatin may have also facilitated interactions with heparan sulfate on vascular endothelial cells and thereby served as another mechanism of clearance of the molecule. Thus in conjunction with the small molecular weight, the heparan sulfate binding properties of follistatin also likely contributed to a lack of effect on muscle following SC administration to mice in our studies.
Taken together with our initial PK/PD data, these properties of FST315 strongly suggest it would be difficult to achieve a systemic effect (at least for muscle-based diseases) without multiple administrations.
Depending on the disease state and therapeutic window of effect, to compensate for the renal clearance/heparan sulfate binding components, FST315 would likely have required much higher doses and/or more frequent administration to achieve an intended pharmacological effect. It is also important to consider from a practical perspective, that it is desirable for a chronically selfadministered biotherapeutic to be optimized in terms of reduced dose frequency for patient convenience/compliance. With these points in mind, we focused our efforts on engineering a follistatin variant with improved in vivo exposure and tissue distribution properties. Fusion of Additional studies are required to determine the relative contribution of increasing the molecular mass versus Fc salvage on the mechanism(s) that led to the improved FST-Fc exposure. In addition, cell-based functional assessments of FST-Fc inhibitory capacity were found to be improved with regards to both activin A and GDF8/myostatin inhbitiory activity, likely due to the forced dimerization of follistatin resulting from the Fc fusion (Table 1A) . Together these improvements in the pharmacokinetic and functional properties of follistatin were sufficient to induce changes in muscle mass in a mouse model of muscle injury when FST-Fc was dosed SC on a daily basis; whereas, previously local IM delivery of FST315 to the injured muscle was required for activity ( Figure 3) . These results strongly supported our hypothesis that improved systemic exposure of follistatin can lead to an enhanced pharmacodynamic effect.
Interestingly, although we observed improvements in the PK/PD properties of FST-Fc relative to native FST315 following systemic administration, comparison of the PK profile of the fusion protein with other published Fc fusion proteins and mAbs of comparable molecular weight showed its clearance was more rapid than anticipated (Vugmeyster, Xu et al. 2012 ). We hypothesized this disconnect was due to the heparan sulfate binding properties of FST-Fc.
FST315 contains a heparan sulfate binding region which has been reported to exhibit high affinity for cell surface heparan sulfate (Inouye, Ling et al. 1992) . Given the relatively high (Table 1B) and functional cell based activity did not show any significant impact in FST-ΔHBS-Fc inhibitory potency towards Activin A and GDF8/myostatin, relative to FST-Fc (Table 1A) . These findings are not consistent with previous speculations that inhibition of activin A by follistatin is modulated by heparin binding to form a more potent and stable inhibitory complex, which may be due in part to the improved inhibitory activity of FST-Fc, relative to FST315 (Table 1A) . Pharmacokinetic assessment of FST-ΔHBS-Fc showed that as hypothesized, removal of the heparin sulfate binding activity lead to further improvements in the systemic exposure (~4.8-fold slower CL) and terminal half-life (~2-fold greater) relative to FST-Fc (Table 2) . Indeed, further improvements were observed in the pharmacodynamic effects of FST-ΔHBS-Fc in the mouse muscle injury model as SC delivery on either a Q2D ( Figure 5A ) or Q7D ( Figure 5B ) dosing frequency could induce robust and significant dose dependant increases in muscle mass.
One aspect of FST-ΔHBS-Fc that was not evaluated in this study was the impact of the N- In summary, to the best of our knowledge, this is the first report demonstrating the successful engineering of a follistatin variant that has the potential to serve as a platform for developing a parenterally administered biotherapeutic as a broad use in multiple disease settings. Our data suggest studies of the activity and/or toxicity of this molecule in additional disease models are warranted. 
